Meningococcus B vaccination: your view

The price of prevention: what now for immunisation against meningococcus B?
The Lancet, Volume 382, Issue 9890, Pages 369 - 370, 3 August 2013
Richard Moxon, Matthew D Snape

Meningococcal sepsis is one of the most dreaded bacterial infections: the death rate remains at about 5% and the effects for survivors include neurological damage, limb amputation, and widespread skin necrosis. There is a compelling case for prevention of meningococcal disease by immunisation. On July 24, 2013, in an interim position statement, the UK Joint Committee on Vaccination and Immunisation (JCVI) concluded that it cannot currently recommend a vaccine (4CMenB, licensed as Bexsero, Novartis Vaccines and Diagnostics, Siena, Italy) for use in the UK routine immunisation programme.

Your view
We invite you to respond to the above Comment, as well as on the JCVI's interim position statement on meningitis B immunisation in the UK. We welcome your contribution to the discussion. 

Share this page:
FaceBookLinkedIntwitterShare by Email

Submit your comments below (400 words max):

Your Comments:
First Name:
Your Email Address:

View this form in a browser window